The GPNMB Knockout MCF-7 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the MCF-7 human breast adenocarcinoma cell line. This product is designed to disrupt the GPNMB gene, introducing a loss-of-function model suitable for studying the roles of glycoprotein nonmetastatic melanoma protein B (GPNMB) in breast cancer biology. The polyclonal nature of the knockout population ensures representation of multiple genetic disruption events, providing a robust tool for functional genomics and phenotypic screening without the clonal selection biases inherent in single-cell-derived lines.
The MCF-7 host cell line is a well-established model of estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), and HER2-negative luminal A breast cancer. Originating from a pleural effusion of a metastatic breast adenocarcinoma, these epithelial cells retain responsiveness to estrogen and are widely employed in studies of hormone-dependent tumor progression, drug sensitivity, and metastasis. MCF-7 cells exhibit adherent growth and are characterized by their dependence on estrogen for proliferation, making them particularly valuable for investigating endocrine therapy resistance and estrogen-regulated signaling networks.
GPNMB functions as a type I transmembrane glycoprotein that mediates cell adhesion and migration through interactions with integrin receptors, including ??v??3 and ??5??1, and the heparan sulfate proteoglycan syndecan-4. Upon ligand engagement, GPNMB activates non-receptor tyrosine kinases FAK and Src, which propagate signals through the PI3K/AKT and MAPK/ERK cascades, ultimately promoting the transcription of matrix metalloproteinases (MMP-2, MMP-9), cyclin D1, and VEGF. Upstream, GPNMB expression is regulated by estrogen/ER??, TGF-??1, and hypoxia-inducible factor HIF-1??, linking it to hormonal and microenvironmental cues in breast cancer. Additional interacting partners, such as CD44, collagen, and fibronectin, further integrate GPNMB into extracellular matrix remodeling and tumor cell dissemination.
In the MCF-7 luminal A breast cancer context, GPNMB knockout is predicted to disrupt integrin-mediated adhesion and motility, attenuate estrogen-responsive growth signaling, and compromise the capacity for metastatic dissemination. Given GPNMB’s role as an immune checkpoint inhibitor that suppresses T-cell activity via syndecan-4 binding, its loss may also alter the immunomodulatory properties of tumor cells. This polyclonal knockout population thus provides a physiologically relevant platform to dissect GPNMB-dependent phenotypes in hormone-responsive breast cancer, including effects on cell proliferation, anchorage-independent growth, and invasive behavior.
Researchers can employ the GPNMB Knockout MCF-7 Polyclonal Cells in a broad array of functional assays, including wound-healing and Boyden chamber migration/invasion studies, cell adhesion to fibronectin or collagen matrices, and xenograft tumor growth models to evaluate metastatic latency and burden. Complementary molecular analyses such as RNA-seq, phospho-signaling profiling (e.g., FAK, AKT, ERK1/2), and co-immunoprecipitation of GPNMB-interacting partners enable mechanistic dissection of GPNMB-driven pathways. These polyclonal knockout cells are also suited for investigating drug resistance mechanisms to anti-estrogens or kinase inhibitors and for validating GPNMB as a therapeutic target. For additional product specifications, performance data, or technical support, please contact Ascent Research.
